Analysts predict that TESARO Inc (NASDAQ:TSRO) will report earnings of ($2.62) per share for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for TESARO’s earnings. The lowest EPS estimate is ($3.05) and the highest is ($2.19). TESARO posted earnings per share of ($0.47) in the same quarter last year, which suggests a negative year-over-year growth rate of 457.4%. The business is expected to issue its next earnings results after the market closes on Tuesday, November 6th.
On average, analysts expect that TESARO will report full-year earnings of ($11.16) per share for the current year, with EPS estimates ranging from ($11.86) to ($10.00). For the next financial year, analysts forecast that the business will report earnings of ($9.07) per share, with EPS estimates ranging from ($10.74) to ($7.80). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover TESARO.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.66) by ($0.38). The firm had revenue of $57.21 million during the quarter, compared to the consensus estimate of $65.50 million. TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. The firm’s quarterly revenue was up 94.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.82) earnings per share.
Shares of TESARO stock opened at $41.75 on Friday. The company has a debt-to-equity ratio of -29.71, a current ratio of 4.11 and a quick ratio of 3.64. The stock has a market capitalization of $2.43 billion, a P/E ratio of -4.55 and a beta of 1.01. TESARO has a fifty-two week low of $25.62 and a fifty-two week high of $119.00.
In other news, Director Arnold L. Oronsky sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $26.77, for a total transaction of $267,700.00. Following the completion of the transaction, the director now directly owns 12,479 shares of the company’s stock, valued at $334,062.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 10,630 shares of company stock valued at $290,424 over the last ninety days. Corporate insiders own 33.70% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Skylands Capital LLC acquired a new position in shares of TESARO during the second quarter worth approximately $182,000. New Jersey Better Educational Savings Trust acquired a new position in shares of TESARO during the third quarter worth approximately $234,000. Stifel Financial Corp acquired a new position in shares of TESARO during the first quarter worth approximately $241,000. Janney Montgomery Scott LLC acquired a new position in shares of TESARO during the second quarter worth approximately $257,000. Finally, BTG Pactual Global Asset Management Ltd acquired a new position in shares of TESARO during the second quarter worth approximately $277,000.
TESARO Company Profile
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Recommended Story: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.